Arcreal

Arcreal is a biotechnology company dedicated to revolutionizing drug discovery through a generative AI platform designed to engineer novel proteins and small molecules. Headquartered in San Francisco, the company focuses on addressing complex biological challenges, such as modulating protein-protein interactions that are often inaccessible to traditional discovery methods. By integrating state-of-the-art deep learning architectures with high-throughput laboratory validation, Arcreal accelerates the design-build-test cycle for new therapeutics. The company's mission is to realize the architecture of life by creating precision medicines for high-need areas in oncology and immunology. Arcreal is currently in the pre-clinical stage and is backed by prominent venture capital firms including Andreessen Horowitz.